The Effect of Evolocumab on In-stent Restenosis in Patients With Acute Coronary Syndrome
Objective To investigate the intervention effect of using an intensified lipid-lowering regimen with evoloc-umab on in-stent restenosis(ISR)after percutaneous coronary intervention(PCI)in patients with acute coronary syn-drome(ACS).Methods A total of 320 patients with acute coronary syndrome admitted to the First People's Hospital of Taicang City from June 2019 to June 2021 were non-randomly selected as the study objects,and divided into 160 pa-tients according to whether or not they were treated with evolocumab.They were divided into statins group and statins+evolocumab group.Blood lipid levels,event-free survival rate and adverse events were compared between the two groups.Results After treatment,the levels of various lipid indexes in both groups were lower than before treatment,and after treatment,the levels of various lipid indexes in statins+evolocumab group were lower than those in statins group,the differences were statistically significant(all P<0.05).The incidence of adverse events in statins+evoloc-umab group was lower than that in statins group,and the difference was statistically significant(P<0.05).The event-free survival rate was 77.50%(124/160)in statins+evolocumab group,which was higher than 64.38%(103/160)in statins group,the difference was statistically significant(χ2=6.685,P<0.05).Conclusion The addition of evolocumab to the post PCI lipid-lowering regimen can effectively reduce the occurrence of in-stent restenosis after coronary inter-vention.
NETL
NSTL
万方数据
